PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection

PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x10(4) PfSPZ-CVac given 28 days apart had 100% vaccine efficacy (VE) against co...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Sean C., Deye, Gregory A., Sim, B. Kim Lee, Galbiati, Shirley, Kennedy, Jessie K., Cohen, Kristen W., Chakravarty, Sumana, KC, Natasha, Abebe, Yonas, James, Eric R., Kublin, James G., Hoffman, Stephen L., Richie, Thomas L., Jackson, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191919/
https://www.ncbi.nlm.nih.gov/pubmed/34048504
http://dx.doi.org/10.1371/journal.ppat.1009594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191919/
https://www.ncbi.nlm.nih.gov/pubmed/34048504
http://dx.doi.org/10.1371/journal.ppat.1009594

Ejemplares similares